# A novel monoclonal antibody generated by immunization with granular tau oligomers binds to tau aggregates at 423-430 amino acid sequence

## TL;DR

A new antibody was developed that specifically targets tau protein aggregates linked to Alzheimer's disease, focusing on a specific amino acid sequence.

## Contribution

A novel monoclonal antibody, 2D6-2C6, was generated and shown to bind specifically to tau aggregates at the 423–430 amino acid sequence.

## Key findings

- 2D6-2C6 showed 3000-fold greater immunoreactivity in transgenic mice compared to non-transgenic mice.
- 2D6-2C6 recognizes neurofibrillary tangles and pretangles in Alzheimer's disease subjects.
- The epitope of 2D6-2C6 is the 423–430 amino acid sequence of the C-terminal region of tau.

## Abstract

Prior to the formation of amyloid fibrils, the pathological hallmark in tau-related neurodegenerative disease, tau monomers aggregate into a diverse range of oligomers. Granular tau oligomers, consisting of approximately 40 tau protein molecules, are present in the prefrontal cortex of patients at Braak stages I-II, preclinical stages of Alzheimer’s disease (AD). Antibodies to granular tau oligomers as antigens have not been reported. Therefore, we generated new rat monoclonal antibodies by immunization with granular tau oligomers. Three antibodies from different hybridoma clones showed stronger immunoreactivity to granular tau oligomers and tau fibrils compared with monomeric tau. Of the three antibodies, 2D6-2C6 showed 3000-fold greater immunoreactivity in P301L-tau transgenic (rTg4510) mice than in non-transgenic mice, while MC1 antibody, which detects pathological conformations of tau, showed a 5.5-fold increase. These results suggest that 2D6-2C6 recognizes aggregates more specifically than MC1. In AD subjects, 2D6-2C6 recognized neurofibrillary tangles and pretangles, and co-localized within AT8-positive cells containing phosphorylated tau aggregates. The epitope of 2D6-2C6 is the 423–430 amino acid (AA) sequence of C-terminal regions. Taken together, a novel monoclonal antibody, 2D6-2C6, generated by immunization with granular tau oligomers binds to tau aggregates at the 423–430 AA sequence.